An interventional study of Transarterial CT angiography in Hemoptysis, sponsored by Wuhan Union Hospital, China. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-13.
Sponsored by Wuhan Union Hospital, China · Not applicable, Interventional, and Treatment
This is a single-arm, exploratory study to evaluate the value of transarterial CT angiography applying Nexaris Angio-CT in the interventional treatment of massive hemoptysis
37 studies on the registry are indexed under Hemoptysis; 6 are open to participants now.
This study's enrollment of 30 is below the median of 73 across 20 interventional studies indexed under Hemoptysis.
Browse Hemoptysis studies →Wuhan Union Hospital, China is the lead sponsor of 229 studies on the registry; 103 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
Device: Transarterial CT angiography
Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
The accuracy rate of transarterial CT angiography in the identification of culprit vessel
The accuracy rate of transarterial CT angiography in the identification of culprit vessel, by calculating the matching rate between Angio-CT and selective angiography findings.
Time frame: Intraoperative phase
In-hospital clinical success
either the complete cessation of hemoptysis or a clinically significant reduction in bleeding, defined as ≤ 5 mL/24 hours of blood-tinged sputum or fresh blood during the hospitalization period.
Time frame: During the postoperative hospitalization period (i.e., the period after bronchial artery embolization until discharge)
Early hemoptysis recurrence rate
Recurrence rate of hemoptysis within 3 months after treatment
Time frame: 3 months after treatment
Technical success rate
Technical success is defined as complete cessation of target blood flow confirmed by DSA
Time frame: Intraoperative phase
Radiation exposure
Radiation exposure data were systematically collected from structured radiation dose reports. For Angio-CT scans, radiation exposure was quantified using the volume CT dose index (CTDIvol) and dose-length product (DLP). For digital subtraction angiography (DSA) and fluoroscopy, air kerma (AK) and dose-area product (DAP) were utilized as metrics.
Time frame: Intraoperative phase
The amount of contrast agent consumed
The amount of contrast agent consumed during treatment
Time frame: Intraoperative phase
Adverse events
AEs were monitored and classified according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The CTCAE system grades AEs on a 5-point scale, with grade ≥ 3 denoting a serious AE.
Time frame: Intraoperative phase and during 3 months after treatment
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Sep 2024, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.